Cosmo NV | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

331 results for “Cosmo NV”

Baldness Drugs Emerge as Wall Street's Next Goldmine as Novel Treatments Near Market

Cosmo Pharmaceuticals and Takeda Renew Multi-Year Manufacturing Agreement for Ulcerative Colitis Treatment

Cosmo Pharmaceuticals Announces Strong 2024 Revenue Growth and Pipeline Advancements

Cosmo Pharmaceuticals Reports Progress in Clinical Trials and Strategic Growth in 2024

Cosmo Pharmaceuticals Launches First-in-Class Acne Treatment Winlevi in Southeast Asia

Cosmo Completes Phase II Enrollment for Novel Rifamycin Enema in Distal Ulcerative Colitis

NanoViricides' NV-387 Shows Broad-Spectrum Antiviral Activity Against 'Tripledemic' Viruses and Smallpox in Animal Models

NanoViricides Develops First-In-Class Broad-Spectrum Antiviral Agent NV-387

NanoViricides' NV-387 Advances to Phase II Clinical Trials for MPox Treatment

NanoViricides Advances NV-387 to Phase II Trials Targeting MPox and Respiratory Infections

Page 1 of 13